載入中
NASDAQHealthcareBiotechnology
最新資料
US$41.94
−US$0.25 · -0.59%
Scholar Rock Holding Corporation is a biopharmaceutical firm dedicated to discovering and advancing treatments for severe medical conditions by targeting the crucial role of protein growth factor signaling. Their lead therapeutic candidate, Apitegromab, an agent designed to inhibit the activation of latent myostatin, has successfully concluded Phase 3 clinical trials for spinal muscular atrophy (SMA). Another key program, SRK-181, is currently undergoing Phase 1 clinical assessment for tackling cancers that exhibit resistance to established checkpoint inhibitor treatments, including anti-PD-1 or anti-PD-L1 antibody therapies. Beyond these, the company cultivates a robust pipeline of innovative potential therapies, aiming to significantly improve the lives of individuals grappling with various severe ailments, such as neurological muscle conditions, malignancies, and fibrotic disorders. In a strategic partnership, Scholar Rock is collaborating with Gilead Sciences, Inc. to identify and develop targeted inhibitors of transforming growth factor beta (TGF-beta) activation, specifically for addressing fibrotic diseases. Established in 2012, Scholar Rock Holding Corporation operates from its headquarters in Cambridge, Massachusetts.
收盤時
US$41.94
−US$0.25 · -0.59%
盤後
US$41.51
−US$0.43 · -1.03%
10月12日 下午5:46 ET
盤中時間採用ET。市場資料可能有所延遲。
Scholar Rock Holding Corporation is a biopharmaceutical firm dedicated to discovering and advancing treatments for severe medical conditions by targeting the crucial role of protein growth factor signaling. Their lead therapeutic candidate, Apitegromab, an agent designed to inhibit the activation of latent myostatin, has successfully concluded Phase 3 clinical trials for spinal muscular atrophy (SMA). Another key program, SRK-181, is currently undergoing Phase 1 clinical assessment for tackling cancers that exhibit resistance to established checkpoint inhibitor treatments, including anti-PD-1 or anti-PD-L1 antibody therapies. Beyond these, the company cultivates a robust pipeline of innovative potential therapies, aiming to significantly improve the lives of individuals grappling with various severe ailments, such as neurological muscle conditions, malignancies, and fibrotic disorders. In a strategic partnership, Scholar Rock is collaborating with Gilead Sciences, Inc. to identify and develop targeted inhibitors of transforming growth factor beta (TGF-beta) activation, specifically for addressing fibrotic diseases. Established in 2012, Scholar Rock Holding Corporation operates from its headquarters in Cambridge, Massachusetts.
日內區間
目前US$41.94
52週區間
目前US$41.94
盤中時間採用ET。市場資料可能有所延遲。
Scholar Rock Holding Corporation is a biopharmaceutical firm dedicated to discovering and advancing treatments for severe medical conditions by targeting the crucial role of protein growth factor signaling. Their lead therapeutic candidate, Apitegromab, an agent designed to inhibit the activation of latent myostatin, has successfully concluded Phase 3 clinical trials for spinal muscular atrophy (SMA). Another key program, SRK-181, is currently undergoing Phase 1 clinical assessment for tackling cancers that exhibit resistance to established checkpoint inhibitor treatments, including anti-PD-1 or anti-PD-L1 antibody therapies. Beyond these, the company cultivates a robust pipeline of innovative potential therapies, aiming to significantly improve the lives of individuals grappling with various severe ailments, such as neurological muscle conditions, malignancies, and fibrotic disorders. In a strategic partnership, Scholar Rock is collaborating with Gilead Sciences, Inc. to identify and develop targeted inhibitors of transforming growth factor beta (TGF-beta) activation, specifically for addressing fibrotic diseases. Established in 2012, Scholar Rock Holding Corporation operates from its headquarters in Cambridge, Massachusetts.
日內區間
目前US$41.94
52週區間
目前US$41.94
獲利能力占已公布營收的百分比。
營收
營業利益
淨利
| 項目（USD） | 2025會計年度 | 2024會計年度 | 2023會計年度 | 2022會計年度 | 2021會計年度 |
|---|---|---|---|---|---|
| 營收 | — | — | — | 3319.3萬 USD | 1881.6萬 USD |
| 銷貨成本 | 2.08億 USD | 193.7萬 USD | 284.4萬 USD | 1.23億 USD | 1.08億 USD |
| 毛利 | −2.08億 USD | −193.7萬 USD | −284.4萬 USD | −8985.1萬 USD | −8965.2萬 USD |
| 研究與開發 | 2.08億 USD | 1.83億 USD | 1.19億 USD | 1.24億 USD | 1.08億 USD |
| 銷售、一般及管理費用 | 1.76億 USD | 6750.4萬 USD | 4939.5萬 USD | 4261.9萬 USD | 4026.9萬 USD |
| 營業費用 | 1.76億 USD | 2.5億 USD | 1.68億 USD | 4451.9萬 USD | 4026.8萬 USD |
| 利息收入 | 1390萬 USD | 1268.2萬 USD | — | — | — |
| 利息支出 | 689.3萬 USD | 683.7萬 USD | — | — | — |
| 折舊和攤銷 | 165.8萬 USD | 193.7萬 USD | 284.4萬 USD | 298.6萬 USD | 262.7萬 USD |
| 營業利益 | −3.85億 USD | −2.52億 USD | −1.71億 USD | −1.34億 USD | −1.3億 USD |
| 淨利 | −3.78億 USD | −2.46億 USD | −1.66億 USD | −1.35億 USD | −1.32億 USD |
公司資料更新於 2026年10月12日。
近期已公布業績
近期已公布業績
第三方分析師預期可能變動，並非 GoAI 建議。
平均目標
US$70.45
上漲空間 67.98%報告持有此股票曝險的交易所交易基金。
Vanguard Morningstar Total Stock Market ETFVTI1.95億0.01%2.3兆 USD0.03%US$381.57-0.10%
iShares Russell 2000 ETFIWM1.23億0.16%787.4億 USD0.19%US$277.9-0.37%
State Street SPDR S&P Biotech ETFXBI7572.53萬0.77%98.74億 USD0.35%US$151.4-1.54%
Vanguard Extended Market ETFVXF6567.84萬0.07%954億 USD0.05%US$233.52-0.63%
iShares Russell 2000 Growth ETFIWO4101.61萬0.29%139.17億 USD0.24%US$353.71-0.86%
Vanguard Russell 2000 ETFVTWO3650.5萬0.20%180億 USD0.06%US$112.27-0.35%
iShares Biotechnology ETFIBB3253.18萬0.30%108.2億 USD0.44%US$204.26-1.08%
Schwab U.S. Small-Cap ETFSCHA2283.86萬0.10%218.24億 USD0.03%US$32.66-0.40%Vanguard Morningstar Total Stock Market ETFVTIiShares Russell 2000 ETFIWMState Street SPDR S&P Biotech ETFXBIVanguard Extended Market ETFVXFiShares Russell 2000 Growth ETFIWOVanguard Russell 2000 ETFVTWOiShares Biotechnology ETFIBBSchwab U.S. Small-Cap ETFSCHAAI 生成內容及延遲市場資料僅供資訊與教育用途，不構成投資建議。
